Literature DB >> 21173308

Enhancement of experimental cutaneous leishmaniasis by Leishmania molecules is dependent on interleukin-4, serine protease/esterase activity, and parasite and host genetic backgrounds.

Virgínia M G Silva1, Daniela F Larangeira, Pablo R S Oliveira, Romina B Sampaio, Paula Suzart, Jorge S Nihei, Márcia C A Teixeira, José O Mengel, Washington L C dos-Santos, Lain Pontes-de-Carvalho.   

Abstract

Most inbred strains of mice, like the BALB/c strain, are susceptible to Leishmania amazonensis infections and resistant to Leishmania braziliensis infections. This parasite-related difference could result from the activity of an L. amazonensis-specific virulence factor. In agreement with this hypothesis, it is shown here that the intravenous injection of BALB/c mice with L. amazonensis amastigote extract (LaE) but not the L. braziliensis extract confers susceptibility to L. braziliensis infection. This effect was associated with high circulating levels of IgG1 anti-L. amazonensis antibodies and with an increase in interleukin-4 (IL-4) production and a decrease in gamma interferon production by draining lymph node cells. Moreover, the effect was absent in IL-4-knockout mice. The biological activity in the LaE was not mediated by amphiphilic molecules and was inhibited by pretreatment of the extract with irreversible serine protease inhibitors. These findings indicate that the LaE contains a virulence-related factor that (i) enhances the Leishmania infection by promoting Th2-type immune responses, (ii) is not one of the immunomodulatory Leishmania molecules described so far, and (iii) is either a serine protease or has an effect that depends on that protease activity. In addition to being Leishmania species specific, the infection-enhancing activity was also shown to depend on the host genetic makeup, as LaE injections did not affect the susceptibility of C57BL/6 mice to L. braziliensis infection. The identification of Leishmania molecules with infection-enhancing activity could be important for the development of a vaccine, since the up- or downmodulation of the immune response against a virulence factor could well contribute to controlling the infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173308      PMCID: PMC3067519          DOI: 10.1128/IAI.00309-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 2.  Leishmania major infection in mice: a model system for the study of CD4+ T-cell subset differentiation.

Authors:  R L Coffman; R Chatelain; L M Leal; K Varkila
Journal:  Res Immunol       Date:  1991-01

3.  Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.

Authors:  Daniela R Faria; Kenneth J Gollob; José Barbosa; Albert Schriefer; Paulo R L Machado; Hélio Lessa; Lucas P Carvalho; Marco Aurélio Romano-Silva; Amélia R de Jesus; Edgar M Carvalho; Walderez O Dutra
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro.

Authors:  K P Chang; D M Dwyer
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

5.  T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice.

Authors:  S Schilling; N Glaichenhaus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species.

Authors:  Márcia Cristina Aquino Teixeira; Regilene de Jesus Santos; Romina Barreto Sampaio; Lain Pontes-de-Carvalho; Washington L C dos-Santos
Journal:  Parasitol Res       Date:  2002-07-06       Impact factor: 2.289

7.  Estimation of population at risk of infection and number of cases of Leishmaniasis.

Authors:  R W Ashford; P Desjeux; P Deraadt
Journal:  Parasitol Today       Date:  1992-03

Review 8.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

9.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

10.  Stage-specific glycosphingolipids from amastigote forms of Leishmania (L.) amazonensis. Immunogenicity and role in parasite binding and invasion of macrophages.

Authors:  A H Straus; S B Levery; M G Jasiulionis; M E Salyan; S J Steele; L R Travassos; S Hakomori; H K Takahashi
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

View more
  4 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

3.  Enhancement of experimental cutaneous leishmaniasis by Leishmania extract: identification of a disease-associated antibody specificity.

Authors:  Virgínia M G Silva; Cíntia F de-Araújo; Isabela C Navarro; Pablo R S Oliveira; Lain Pontes-de-Carvalho
Journal:  BMC Res Notes       Date:  2015-05-14

4.  Leishmania braziliensis and Leishmania amazonensis amastigote extracts differ in their enhancement effect on Leishmania infection when injected intradermally.

Authors:  Cintia F de Araújo; Virgínia M G Silva; Andre Cronemberger-Andrade; Luciana S Aragão-França; Viviane C J Rocha; Priscila S L Santos; Lain Pontes-de-Carvalho
Journal:  BMC Res Notes       Date:  2014-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.